Dynamic42 opens new possibilities for tissue-based drug research at ELRIG 2026
Dynamic42's open-top biochip brings tissue slices and controlled flow together for drug research.
2026-10-17
Physicians Committee Champions National Institutes of Health Program to Qualify Human-Based Methods for Drug Development
NIH-funded tissue-chip centers seek to make human-based drug testing tools credible for industry and FDA use.
2026-10-10
Human body on a chip
Multi-organ chips may need shared cellular origins, not just more connected tissues.
2026-10-09
90% of drugs that pass animal tests fail in humans; FDA makes room for alternatives
FDA rules now recognize organs-on-chips and other human-based tests as alternatives to animal studies.
2026-10-09
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
FDA policy may speed organoid and organ-on-a-chip adoption, but trust in their data remains the crucial hurdle.
2026-10-07
Engineering human multi-organ tissue chip niches for drug absorption, distribution, metabolism, excretion and toxicity prediction
Multi-organ chips may improve drug predictions, but preserving each tissue's unique biology remains the central engineering challenge.
2026-10-06
Organoids, Organ-on-a-Chip, and the Case for Online LC–MS
Automated online LC-MS could help researchers analyze scarce, complex samples from organoid and organ-on-a-chip models.
2026-09-29
Researchers develop technology for real-time monitoring of Parkinson's treatments
A brainstem organoid chip tracks dopamine responses to Parkinson’s treatments in real time.
2026-09-28
From dietary exposure to systemic toxicity: organ-on-chip and multi-organ microphysiological systems for green food toxicology
Organ-on-chip models could connect dietary exposure, metabolism, and organ injury in more human-relevant food safety tests.
2026-09-16
Qureator
Qureator develops Curiochips, a three-dimensional organ-on-chip platform for modeling human biology. The company combines engineered tissue systems with data analysis to study disease and treatment responses during preclinical drug development.
2026-09-14
DLOC Biosystems
DLOC Biosystems develops organ-on-chip devices and automated systems for connecting multiple tissue models. Its platforms combine three-dimensional scaffolds, controlled fluid handling and tissue measurements to support preclinical studies of drug effects and organ interactions.
2026-09-14
Syntopia
Syntopia combines microfluidic systems, perfused human tissue cultures and computational models to study drug responses. Its platform generates spatial and temporal measurements from three-dimensional models, with a focus on evaluating antibody-drug conjugates before clinical testing.
2026-09-14